Metabolomics Panel for Early Acute Myocardial Infarction Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for acute myocardial infarction (AMI) in the hyperacute phase (<6 hours) are inadequate due to atypical symptoms, low specificity of electrocardiograms, and insufficient diagnostic performance of traditional biomarkers like troponin.
Innovation Solution
A method involving non-targeted metabolomics to identify a combination of 13 biomarkers (pentadecanoate, tryptophan, laurate, methionine sulfoxide, methylpalmitate, acetylcarnitine, 3-methyl-2-oxobutyrate, oxindolylalanine, asparagine, methionine, N-palmitoylglycine, carnitine, and phenylalanine) for early diagnosis of AMI, using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and statistical analysis to establish a diagnostic model.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional biomarkers like troponin are used for diagnosis, then diagnostic accuracy is improved, but diagnostic performance in the hyperacute phase remains insufficient
Solution Approach 1:
The patent combines multiple metabolite markers (pentadecanoate, tryptophan, laurate, methionine sulfoxide, methylpalmitate, acetylcarnitine, 3-methyl-2-oxobutyrate, oxindolylalanine, asparagine, methionine, N-palmitoylglycine, carnitine, and phenylalanine) into a composite diagnostic panel. This composite approach leverages the complementary strengths of different metabolites to achieve both high diagnostic accuracy and reliable early detection in the hyperacute phase, resolving the contradiction between general accuracy and phase-specific reliability.
Solution Approach 2:
The patent identifies and measures specific metabolite concentration changes in the hyperacute phase that differ from traditional biomarkers. By monitoring parameters such as pentadecanoate and tryptophan levels that change rapidly in the first few hours after onset, the system achieves reliable early diagnosis while maintaining overall diagnostic accuracy across different time points.
2Speed
If electrocardiogram is used for diagnosis, then diagnostic speed is improved, but accuracy for non-ST-elevation AMI remains low
Solution Approach 1:
The patent introduces metabolite biomarkers as intermediary indicators that bridge the gap between rapid electrocardiogram screening and definitive diagnosis. These metabolite levels serve as intermediate evidence that can confirm or refute electrocardiogram findings, particularly for non-ST-elevation cases where ECG alone is insufficient, thereby improving accuracy without sacrificing the initial screening speed.
3Loss of time
If rapid diagnosis within 6 hours is achieved, then treatment effectiveness is improved, but diagnostic reliability is reduced due to atypical symptoms
Solution Approach 1:
The patent measures metabolite levels immediately upon patient presentation, performing the diagnostic action in advance before atypical symptoms can fully manifest or before clinical uncertainty develops. By establishing baseline metabolite concentrations in the hyperacute phase, the system enables rapid diagnosis within 6 hours while maintaining reliability through objective biochemical evidence that is not influenced by evolving clinical presentations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables efficient detection of early myocardial infarction, reduces erroneous diagnoses, and improves the effectiveness of timely interventions such as thrombolytic therapy and interventional surgery.
Implementation Method 1
using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
Implementation Method 2
using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
Data Source
AI summary
The present invention provides a method for early diagnosis of acute myocardial infarction and for predicting whether an individual is suffering from acute myocardial infarction. The method includes: providing a liquid sample derived from the individual; detecting a concentration or content of the biomarker in the liquid sample; and determining whether the individual is suffering from acute myocardial infarction according to the content. This method can be utilized for efficient detection and risk stratification of early myocardial infarction, accurate diagnosis and evaluation of patients with acute myocardial infarction and potential high-risk people, so as to improve the early diagnosis rate of acute myocardial infarction, guide the implementation of precise medical strategy, and thus improve the rescue level of acute myocardial infarction.